Literature DB >> 6854019

A phenotypically normal revertant of an adenosine deaminase-deficient lymphoblast cell line.

J Uberti, W D Peterson, J J Lightbody, R M Johnson.   

Abstract

Two lymphoblast lines from a patient with partial adenosine deaminase deficiency have been obtained. The patient has a T cell deficiency, with normal B cell function, and has been successfully treated by multiple partial exchange transfusions with normal erythrocytes. The patient's lymphocytes have about 8% of normal adenosine deaminase activity. The derived lymphoblast line that initially had low adenosine deaminase activity has undergone spontaneous reversion to normal enzyme activity. The HL-A types remain the same as the patient's. Both cell lines have the same HL-A types, and eight isoenzymes are identical. In addition, the isoenzymes of a fibroblast line derived earlier, GM-2445, are identical with those in our lymphoblast lines. The following characteristics of the enzyme in the cell lines are normal: Km, Vmax, inhibitor sensitivity, heat sensitivity, and m.w. This suggests, but does not prove, that the low adenosine deaminase activity in this patient is caused by underproduction of a normal enzyme, and the observed reversion to normal activity in one line is a correction of this regulation defect.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6854019

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Incomplete penetrance in primary immunodeficiency: a skeleton in the closet.

Authors:  Conor Gruber; Dusan Bogunovic
Journal:  Hum Genet       Date:  2020-02-17       Impact factor: 4.132

2.  Reversion mutations in patients with leukocyte adhesion deficiency type-1 (LAD-1).

Authors:  Gulbu Uzel; Emilia Tng; Sergio D Rosenzweig; Amy P Hsu; Jacqueline M Shaw; Mitchell E Horwitz; Gilda F Linton; Stacie M Anderson; Martha R Kirby; Jaõ B Oliveira; Margaret R Brown; Thomas A Fleisher; S K Alex Law; Steven M Holland
Journal:  Blood       Date:  2007-09-17       Impact factor: 22.113

3.  Novel splicing, missense, and deletion mutations in seven adenosine deaminase-deficient patients with late/delayed onset of combined immunodeficiency disease. Contribution of genotype to phenotype.

Authors:  I Santisteban; F X Arredondo-Vega; S Kelly; A Mary; A Fischer; D S Hummell; A Lawton; R U Sorensen; E R Stiehm; L Uribe
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

4.  Identification of a point mutation in the adenosine deaminase gene responsible for immunodeficiency.

Authors:  D T Bonthron; A F Markham; D Ginsburg; S H Orkin
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

5.  Somatic mosaicism for a newly identified splice-site mutation in a patient with adenosine deaminase-deficient immunodeficiency and spontaneous clinical recovery.

Authors:  R Hirschhorn; D R Yang; A Israni; M L Huie; D R Ownby
Journal:  Am J Hum Genet       Date:  1994-07       Impact factor: 11.025

6.  Adenosine deaminase (ADA) deficiency in cells derived from humans with severe combined immunodeficiency is due to an aberration of the ADA protein.

Authors:  D Valerio; M G Duyvesteyn; H van Ormondt; P Meera Khan; A J van der Eb
Journal:  Nucleic Acids Res       Date:  1984-01-25       Impact factor: 16.971

7.  Paradoxical expression of adenosine deaminase in T cells cultured from a patient with adenosine deaminase deficiency and combine immunodeficiency.

Authors:  F X Arredondo-Vega; J Kurtzberg; S Chaffee; I Santisteban; E Reisner; M S Povey; M S Hershfield
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

Review 8.  Genetic Mosaicism as a Cause of Inborn Errors of Immunity.

Authors:  Jahnavi Aluri; Megan A Cooper
Journal:  J Clin Immunol       Date:  2021-04-16       Impact factor: 8.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.